Elevation Oncology在 2025年美国癌症研究协会 (AACR)年会上展示了 EO-1022的临床前概念验证数据-动脉网

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

CISION 等信源发布 2025-04-26 01:00



可切换为仅中文







-- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple

-- EO-1022 是一种潜在差异化的 HER3 ADC，旨在满足多个领域中显著未满足的需求

solid tumors --

实体瘤 --

-- On-track to file IND application in 2026 --

-- 预计在2026年提交IND申请 --

BOSTON

波士顿

，

April 25, 2025

2025年4月25日

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq:

/PRNewswire/ -- Elevation Oncology, Inc.（纳斯达克：

ELEV

电梯

), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022.

），这是一家创新的肿瘤学公司，专注于发现和开发选择性癌症治疗方法，以治疗在多种实体瘤中具有显著未满足医疗需求的患者，今天宣布了其新型HER3抗体药物偶联物（ADC）EO-1022的新临床前概念验证数据。

The data will be presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held .

数据将在美国癌症研究协会（AACR）2025年年会上以最新海报展示的形式呈现。

April 25-30

4月25日至30日

在

Chicago, Illinois

伊利诺伊州芝加哥市

。

'We designed EO-1022 with several notable features, including glycan site-specific conjugation and MMAE payloads, in order to address the significant need for a novel HER3 ADC that can potentially deliver improved efficacy and safety to patients with a range of solid tumors,' said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.

“我们设计的EO-1022具有几个显著特点，包括聚糖位点特异性偶联和MMAE载荷，旨在满足对一种新型HER3 ADC的重大需求，这种ADC有可能为多种实体瘤患者提供更高的疗效和安全性，”Elevation Oncology总裁兼首席执行官Joseph Ferra表示。

'Today, we are excited to share preclinical proof-of-concept data for EO-1022, which indicate enhanced stability and anti-tumor activity than benchmark HER3 ADCs in the models tested .

“今天，我们很高兴分享EO-1022的临床前概念验证数据，这些数据显示在测试的模型中，EO-1022比基准HER3 ADC具有更高的稳定性和抗肿瘤活性。

in vitro

体外

and

和

in vivo.

体内。

We believe these findings support the potential of EO-1022 in treating multiple HER3-expressing cancers and look forward to progressing this program toward the clinic.'

我们相信这些研究结果支持了EO-1022在治疗多种表达HER3的癌症中的潜力，并期待将这一项目推向临床。

EO-1022 is an ADC containing seribantumab, a fully human IgG2 anti-HER3 monoclonal antibody, which is site-specifically conjugated at glycan to the monomethyl auristatin E (MMAE) payload with a drug-to-antibody ratio (DAR) of 4. Elevation Oncology designed EO-1022 leveraging the site-specific ADC technology platform licensed from Synaffix B.V.

EO-1022 是一种抗体药物偶联物 (ADC)，包含 seribantumab，这是一种全人源 IgG2 抗 HER3 单克隆抗体，通过糖链位点特异性地与单甲基澳瑞他汀 E (MMAE) 有效载荷结合，药物抗体比 (DAR) 为 4。Elevation Oncology 利用从 Synaffix B.V. 获得授权的位点特异性 ADC 技术平台设计了 EO-1022。

Elevation Oncology is developing EO-1022 for the treatment of solid tumors that express HER3, including breast cancer and non-small cell lung cancer. Elevation Oncology expects to file an Investigational New Drug (IND) application for EO-1022 in 2026..

Elevation Oncology正在开发EO-1022，用于治疗表达HER3的实体瘤，包括乳腺癌和非小细胞肺癌。Elevation Oncology预计将在2026年为EO-1022提交研究性新药（IND）申请。

In a poster titled, 'Preclinical discovery and characterization of EO-1022, a site-specific glycan-conjugated anti-HER3 vc-MMAE ADC for treating solid tumors,' Elevation Oncology scientists will present

在题为“EO-1022的临床前发现与特性研究，一种用于治疗实体瘤的位点特异性糖链偶联抗HER3 vc-MMAE ADC”的海报中，Elevation Oncology的科学家们将展示相关内容。

in vitro

体外

and

和

in vivo

体内

data that show:

显示以下内容的数据：

EO-1022 is highly stable in human serum, with a homogenous DAR of 4 and minimal free payload compared to seribantumab-vcMMAE and patritumab-DXd, two benchmark HER3 ADCs, both of which use stochastic conjugation. These findings illustrate that a key feature of EO-1022 is minimal systemic exposure to free payload, potentially resulting in reduced payload-associated toxicity in patients and an improved safety profile..

EO-1022在人血清中具有高度稳定性，其均一的药物抗体比（DAR）为4，与采用随机偶联的两种基准HER3抗体药物偶联物（ADC）——seribantumab-vcMMAE和patritumab-DXd相比，游离有效载荷极少。这些研究结果表明，EO-1022的一个关键特性是游离有效载荷的系统暴露量极低，这可能降低患者中与有效载荷相关的毒性，并改善安全性特征。

EO-1022 exhibits potent

EO-1022 表现出强大的

in vitro

体外

cytotoxicity that is dependent on HER3 expression levels.

依赖于HER3表达水平的细胞毒性。

EO-1022 elicits anti-tumor activity in

EO-1022 在以下方面表现出抗肿瘤活性

in vivo

体内

models of low, medium and high HER3 expression levels, including in a patient derived xenograft (PDX) model of low HER3-expressing EGFR-mutant lung cancer.

包括低、中、高HER3表达水平的模型，以及低HER3表达的EGFR突变肺癌患者来源的异种移植（PDX）模型。

The poster presentation is now available in the 'Publications' section of Elevation Oncology's website:

海报展示现已在Elevation Oncology公司网站的“出版物”部分提供：

https://elevationoncology.com/resources/publications/

。

About EO-1022

关于EO-1022

Elevation Oncology is developing EO-1022, a potentially differentiated HER3 ADC for the treatment of HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer. EO-1022 consists of seribantumab, a fully human IgG2 anti-HER3 antibody, site-specifically conjugated at glycan to the MMAE payload with a DAR of 4.

Elevation Oncology正在开发EO-1022，一种潜在差异化的HER3抗体药物偶联物（ADC），用于治疗表达HER3的实体瘤，包括乳腺癌和非小细胞肺癌。EO-1022由seribantumab组成，这是一种完全人源化的IgG2抗HER3抗体，通过糖链位点特异性地与MMAE有效载荷结合，药物抗体比（DAR）为4。

It leverages seribantumab's desirable internalization properties and advanced site-specific ADC technology which makes possible the use of the potent cytotoxic MMAE payload. Elevation Oncology expects to file an IND application in 2026..

它利用了seribantumab理想的内化特性和先进的位点特异性ADC技术，使得使用高效细胞毒性MMAE载荷成为可能。Elevation Oncology预计将在2026年提交IND申请。

About Elevation Oncology, Inc.

关于Elevation Oncology公司

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our antibody-drug conjugate (ADC) expertise to advance EO-1022, a HER3 ADC for the treatment of patients with HER3-expressing solid tumors.

Elevation Oncology是一家创新的肿瘤学公司，专注于发现和开发选择性癌症疗法，以治疗一系列具有显著未满足医疗需求的实体瘤患者。我们正在利用我们在抗体药物偶联物（ADC）方面的专业知识推进EO-1022，这是一种用于治疗HER3表达实体瘤患者的HER3 ADC。

EO-1022 is currently progressing through preclinical development, with an investigational new drug (IND) application expected in 2026. For more information, visit .

EO-1022 目前正在进行临床前开发，预计将在 2026 年提交试验性新药 (IND) 申请。欲了解更多信息，请访问。

www.ElevationOncology.com

。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated clinical and preclinical development activities, expected timing of regulatory filings, potential benefits of product candidates, potential market opportunities for product candidates and the ability of product candidates to treat their targeted indications.

本新闻稿包含1995年《私人证券诉讼改革法案》“安全港”条款所指的前瞻性声明，包括但不限于预期的临床和临床前开发活动、监管文件提交的预期时间、产品候选物的潜在益处、产品候选物的潜在市场机会以及产品候选物治疗其目标适应症的能力。

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'will,' 'would,' and other words and terms of similar meaning.

所有非历史事实的陈述都可能被视为前瞻性陈述。这些前瞻性陈述可能伴随诸如“目标”、“预期”、“相信”、“可能”、“估计”、“预计”、“预测”、“目的”、“打算”、“或许”、“计划”、“可能”、“潜在”、“将会”、“应该”等词语及其他类似含义的词汇和术语。

Although Elevation Oncology believes that the expectations reflected in such forward-looking statements are reasonable, Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain.

尽管Elevation Oncology认为这些前瞻性陈述中反映的预期是合理的，但Elevation Oncology无法保证未来事件、结果、行动、活动水平、表现或成就，且生物技术开发和潜在监管批准的时间与结果本质上存在不确定性。

Forward-looking statements are subject to risks and uncertainties that may cause Elevation Oncology's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Elevation Oncology's ability to advance its product candidates, the timing and results of preclinical studies and clinical trials, approvals and commercialization of product candidates, the receipt and timing of potential regulatory designations, Elevation Oncology's ability to fund development activities and achieve development g.

前瞻性声明受到风险和不确定性的制约，可能导致Elevation Oncology的实际活动或结果与任何前瞻性声明中表达的内容存在显著差异，包括与Elevation Oncology推进其产品候选物的能力、临床前研究和临床试验的时间与结果、产品候选物的批准和商业化、潜在监管认定的收据与时间、Elevation Oncology为开发活动提供资金并实现开发目标的能力相关的风险和不确定性。

Elevation Oncology Investor and Media Contact

Elevation Oncology 投资者和媒体联系人

Gracie Tong

Grace Tong

Senior Director, Investor Relations and Corporate Communications

高级总监，投资者关系和企业传播

gtong@elevationoncology.com

SOURCE Elevation Oncology

源高程肿瘤学

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?